Stevanato Group (NYSE:STVN) Releases FY 2024 Earnings Guidance

Stevanato Group (NYSE:STVN) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.517-0.539 for the period, compared to the consensus earnings per share estimate of 0.490. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Stevanato Group also updated its FY24 guidance to €0.47-0.49 EPS.

Wall Street Analyst Weigh In

STVN has been the subject of several analyst reports. Citigroup decreased their target price on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley cut their price target on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th.

Stevanato Group Trading Up 0.8 %

Shares of NYSE STVN opened at €22.72 ($24.97) on Friday. The stock’s 50 day moving average price is €19.68 and its two-hundred day moving average price is €20.33. Stevanato Group has a 52-week low of €16.56 ($18.20) and a 52-week high of €34.73 ($38.16). The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.13 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). The firm had revenue of €277.90 million for the quarter, compared to analyst estimates of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.16 EPS. As a group, equities research analysts predict that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.